Search results for " DIABETES MELLITUS"

showing 10 items of 309 documents

Latvijas Universitātes Raksti. 755. sēj.

2010

:MEDICINE [Research Subject Categories]Iron deficiencyDzelzs deficīts2. tipa cukura diabētsVairogdziedzera vēzisUzmanības deficīta sindromsAerobās darbspējasEndoskopiska retrogrāda holangiopankreatogrāfijaMedicīniskās palīdzības pieejamībaPsoriāzeSkin precursor cellsBody massCitokīniType 2 diabetes mellitusKoagulāzes negatīvie stafilokoki
researchProduct

Grip Strength, Neurocognition, and Social Functioning in People WithType-2 Diabetes Mellitus, Major Depressive Disorder, Bipolar Disorder, and Schizo…

2020

[Background] Frailty is a common syndrome among older adults and patients with several comorbidities. Grip strength (GS) is a representative parameter of frailty because it is a valid indicator of current and long-term physical conditions in the general population and patients with severe mental illnesses (SMIs). Physical and cognitive capacities of people with SMIs are usually impaired; however, their relationship with frailty or social functioning have not been studied to date. The current study aimed to determine if GS is a valid predictor of changes in cognitive performance and social functioning in patients with type-2 diabetes mellitus and SMIs.

:Psychiatry and Psychology::Mental Disorders::Mood Disorders::Affective Disorders Psychotic::Bipolar Disorder [Medical Subject Headings]:Organisms::Eukaryota::Animals::Chordata::Vertebrates::Mammals::Primates::Haplorhini::Catarrhini::Hominidae::Humans [Medical Subject Headings]0302 clinical medicine:Psychiatry and Psychology::Mental Disorders::Mood Disorders::Depressive Disorder::Depressive Disorder Major [Medical Subject Headings]Social functioningPsychology030212 general & internal medicineType-2 diabetes mellitusCognitive performancecognitive performanceGeneral PsychologyOriginal Research:Persons::Persons::Age Groups::Adult::Aged [Medical Subject Headings]:Persons::Persons::Patients::Outpatients [Medical Subject Headings]education.field_of_studyFrailtyCognition:Disciplines and Occupations::Natural Science Disciplines::Physics::Electronics [Medical Subject Headings]Type-2 diabetesmellitusFragilidadDiabetes mellitus tipo 2SchizophreniaTrastornos mentalesMajor depressive disorder:Diseases::Nutritional and Metabolic Diseases::Metabolic Diseases::Glucose Metabolism Disorders::Diabetes Mellitus::Diabetes Mellitus Type 2 [Medical Subject Headings]PsychologyClinical psychologyFuerza de la manoPopulationlcsh:BF1-990frailty03 medical and health sciencessevere mental illness:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Epidemiologic Study Characteristics as Topic::Epidemiologic Studies::Cohort Studies::Longitudinal Studies::Follow-Up Studies [Medical Subject Headings]Severe mental illnessmedicine:Psychiatry and Psychology::Mental Disorders::Schizophrenia and Disorders with Psychotic Features::Schizophrenia [Medical Subject Headings]Effects of sleep deprivation on cognitive performanceBipolar disordereducation:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Regression Analysis [Medical Subject Headings]:Psychiatry and Psychology::Psychological Phenomena and Processes::Mental Processes::Cognition [Medical Subject Headings]:Analytical Diagnostic and Therapeutic Techniques and Equipment::Diagnosis::Diagnostic Techniques and Procedures::Physical Examination::Muscle Strength::Hand Strength [Medical Subject Headings]Type 2 Diabetes Mellitustype-2 diabetes mellitusmedicine.diseasesocial functioninglcsh:PsychologyGrip strengthgrip strengthInteracción socialNeurocognitive:Analytical Diagnostic and Therapeutic Techniques and Equipment::Investigative Techniques::Epidemiologic Methods::Statistics as Topic::Analysis of Variance [Medical Subject Headings]030217 neurology & neurosurgeryFrontiers in Psychology
researchProduct

Metabolic signatures across the full spectrum of non-alcoholic fatty liver disease.

2022

Funder: European Commission

ALTtype 2 diabetes mellitusROC receiving operator characteristicaspartate aminotransferaseHSDLDL low-density lipoproteinUHPLC ultrahigh-performance liquid chromatographyROCHCCNon-alcoholic steatohepatitisGCPCANASHGastroenterology2-HB 2-hydroxybutanoic acid; 3-HB 3-hydroxybutanoic acid; ALT alanine aminotransferase; AST aspartate aminotransferase; CE cholesterol ester; Cer ceramide; FFA free fatty acid; FLIP Fatty Liver Inhibition of Progression; Fibrosis; GC gas chromatography; HCC hepatocellular carcinoma; HSD honest significant difference; LC lipid cluster; LDL low-density lipoprotein; LM lipid and metabolite; LMC lipid metabolite and clinical variable; LPC lysophosphatidylcholine; Lipidomics; Mass spectrometry; Metabolomics; NAFL non-alcoholic fatty liver; NAFLD non-alcoholic fatty liver disease; NAS NASH activity score; NASH non-alcoholic steatohepatitis; NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network; NRR non-rejection rate; Non-alcoholic steatohepatitis; PC(O) ether PC; PC phosphatidylcholine; PCA principal component analysis; PE phosphatidylethanolamine; QTOFMS quadrupole-time-of-flight mass spectrometry; ROC receiving operator characteristic; SAF steatosis activity and fibrosis; SM sphingomyelin; T2DM type 2 diabetes mellitus; TG triacylglycerol; UHPLC ultrahigh-performance liquid chromatographySAFSAF steatosis activity and fibrosisLM lipid and metabolitehonest significant differenceHSD honest significant differenceTG triacylglycerolnon-rejection ratecholesterol esterPCPEGC gas chromatographyfree fatty acidFLIPNASH non-alcoholic steatohepatitisNIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkBIOMARKERST2DMPE phosphatidylethanolamineLDLlipidNAFLDFFA free fatty acid2-HBMetabolomicsNAFL non-alcoholic fatty liverLMCphosphatidylcholineScience & TechnologySM sphingomyelinGastroenterology & HepatologyMass spectrometryactivitynutritional and metabolic diseasesT2DM type 2 diabetes mellitusACIDSreceiving operator characteristicdigestive system diseasesquadrupole-time-of-flight mass spectrometryLC lipid clusterlow-density lipoproteinNAS2-HB 2-hydroxybutanoic acidNAS NASH activity scoreQTOFMSether PCNRRSCORING SYSTEMprincipal component analysisgas chromatographyLC2-hydroxybutanoic acidPROGRESSIONAST aspartate aminotransferaseLMPC phosphatidylcholinePC(O)MARKERSUHPLCsteatosisTOOLImmunology and AllergyINSULIN-RESISTANCECerSMFatty Liver Inhibition of Progressionhepatocellular carcinoma2-HB 2-hydroxybutanoic acid NIDDK NASH-CRN National Institute of Digestive Diseases and Kidney NASH Clinical Research Network NRR non-rejection rate Non-alcoholic steatohepatitis PC(O) ether PC PC phosphatidylcholine PCA principal component analysis PE phosphatidylethanolamine QTOFMS quadrupole-time-of-flight mass spectrometry ROC receiving operator characteristic SAF steatosis activity and fibrosis SM T2DM type 2 diabetes mellitus TG triacylglycerol UHPLC ultrahigh-performance liquid chromatographyultrahigh-performance liquid chromatographyCELPC3-HBNAFLnon-alcoholic fatty liverTGtriacylglycerolNRR non-rejection rateLife Sciences & BiomedicineNAFLD non-alcoholic fatty liver diseaseFLIP Fatty Liver Inhibition of Progressionalanine aminotransferasemetaboliteCer ceramideCE cholesterol estersphingomyelinlysophosphatidylcholineand fibrosisALT alanine aminotransferaseInternal MedicineceramideNational Institute of Digestive Diseases and Kidney NASH Clinical Research NetworkAST3-HB 3-hydroxybutanoic acidQTOFMS quadrupole-time-of-flight mass spectrometryPCA principal component analysisLPC lysophosphatidylcholineHepatologynon-alcoholic fatty liver diseaseand clinical variablePC(O) ether PC3-hydroxybutanoic acidFibrosisNASH activity scoreNIDDK NASH-CRNlipid clusterlipid and metabolitephosphatidylethanolamineLipidomicsLMC lipid metabolite and clinical variableFFAHCC hepatocellular carcinomaJHEP reports : innovation in hepatology
researchProduct

Activation of AMPK by medicinal plants and natural products: Its role in type 2 diabetes mellitus

2019

Type-2 Diabetes (T2D) is a metabolic disease characterized by permanent hyperglycemia, whose development can be prevented or delayed by using therapeutic agents and implementing lifestyle changes. Some therapeutic alternatives include regulation of glycemia through modulation of different mediators and enzymes, such as AMP-activated protein kinase (AMPK), a highly relevant cellular energy sensor for metabolic homeostasis regulation, with particular relevance in the modulation of liver and muscle insulin sensitivity. This makes it a potential therapeutic target for antidiabetic drugs. In fact, some of them are standard drugs used for treatment of T2D, such as biguanides and thiazoli-dindione…

AMPKCIENCIAS MÉDICAS Y DE LA SALUDBiguanidesAMP-Activated Protein KinasesPharmacologyResveratrolCarbohydrate metabolismNATURAL PRODUCTS03 medical and health scienceschemistry.chemical_compound0302 clinical medicineBerberineDiabetes mellitusDrug DiscoveryHumansHypoglycemic AgentsMedicineTYPE 2 DIABETES MELLITUSProtein kinase A030304 developmental biologyPharmacologychemistry.chemical_classificationBiological Products0303 health sciencesPlants Medicinalbusiness.industryType 2 Diabetes MellitusAMPKGeneral MedicineBioquímica y Biología Molecularmedicine.diseaseANTIDIABETIC DRUGSMedicina BásicaGlucoseEnzymeDiabetes Mellitus Type 2chemistry030220 oncology & carcinogenesisThiazolidinedionesbusinessMEDICINAL PLANTS
researchProduct

CLINICAL CHARACTERISTICS AND PLASMA LIPIDS IN SUBJECTS WITH FAMILIAL COMBINED HYPOLIPIDEMIA: A POOLED ANALYSIS

2013

Background. Angiopoietin-like 3 (ANGPTL3) regulates lipoprotein metabolism by modulating extracellular lipases. Loss-of function mutations in ANGPTL3 gene cause familial combined hypolipidemia (FHBL2). The mode of inheritance and hepatic and vascular consequences of FHBL2 have not been fully elucidated. To get further insights on these aspects, we re-evaluated the clinical and the biochemical characteristics of all reported cases of FHBL2. Methods and Results. One hundred fteen FHBL2 individuals carrying 13 different mutations in the ANGPTL3 gene (14 homozygotes, 8 compound heterozygotes and 93 heterozygotes) and 402 controls were considered. Carriers of 2 mutant alleles had undetectable pl…

ANGPTL3 mutations; angiopoietin-like 3; cardiovascular disease; diabetes mellitus; fatty liverSettore MED/09 - Medicina InternaCompound heterozygosityBiochemistryCohort StudiesHypobetalipoproteinemiasEndocrinologyANGPTL3cardiovascular diseaseGenotypeChildLipoproteinclinical characteristicsAged 80 and overbiologydiabetes mellituFatty liverHomozygoteLipoprotein(a)Middle AgedANGPTL3 mutationLipidsCardiovascular Diseasesdiabetes mellitusANGPTL3 Familial combined hypolipidemia LipoproteinAdultmedicine.medical_specialtyHeterozygoteANGPTL3; Familial combined hypolipidemia; clinical characteristicsAdolescentEvinacumabQD415-436Young AdultDiabetes mellitusInternal medicinemedicineHumansANGPTL3 mutationsAlleleFamilial combined hypolipidemiaAgedAngiopoietin-Like Protein 3fatty liverangiopoietin-like 3Cell Biologymedicine.diseaseEndocrinologyAngiopoietin-like ProteinsGene Expression RegulationMutationbiology.proteinPatient-Oriented and Epidemiological ResearchAngiopoietinsLipoproteinLipoprotein(a)
researchProduct

Influence of family history to type 2 diabetes on the body composition and homeostasis model assessment: a comparison between young active and sedent…

2006

Obiettivo. La storia familiare (family history, FH) per il diabete mellito (DM) di tipo 2 è un fattore di rischio per lo sviluppo della malattia, inducendo precoci modificazioni metaboliche e antropometriche in soggetti sedentari. Lo scopo di questo lavoro era studiare l’influenza di FH al DM sulla composizione corporea e sul metabolismo del glucosio in giovani uomini sedentari ed attivi. Metodi. In un’analisi trasversale, sono stati registrati dati antropometrici, composizione corporea (tramite BIA), insulina e glucosio plasmatici in 60 giovani siciliani sani (31 atleti e 29 soggetti sedentari); FH è stata definita come FH+ se il soggetto aveva riferito di avere almeno un membro della fami…

Adult Body Composition/genetics Body Mass Index Cross-Sectional Studies Diabetes Mellitus Type 2/genetics Exercise Humans Male Waist-Hip RatioSettore BIO/09 - Fisiologia
researchProduct

SHIP2: A “NEW” Insulin Pathway Target for Aging Research

2014

Strong evidence suggests that systemic inflammation and central adiposity contribute to and perpetuate metabolic syndrome. All of these alterations predispose individuals to type 2 diabetes mellitus (T2DM), cardiovascular disease, as well as Alzheimer's disease (AD), all characterized by chronic inflammatory status. On the other hand, extensive abnormalities in insulin and insulin-like growth factor I (IGF-I) and IGF-II signaling mechanisms in brains with AD have been demonstrated, suggesting that AD could be a third form of diabetes. The Src homology domain-containing inositol 5-phosphatase 2 (SHIP2) has an important role in the insulin pathway because its over-expression causes impairment…

AdultAgingmedicine.medical_specialtymedicine.medical_treatmentDiseaseBiologySystemic inflammationPolymorphism Single Nucleotidepolymorphismchemistry.chemical_compounddomain-containing inositol 5-phosphatase 2 (SHIP2) insulin-like growth factor I (IGF-I) type 2 diabetes mellitus (T2DM)INFLAMMATIONGene FrequencyAlzheimer DiseaseDiabetes mellitusInternal medicinemedicineHumansInsulinSettore MED/05 - Patologia ClinicaSNPInositolAgedSettore MED/04 - Patologia GeneraleALZHEIMER’S DISEASEResearchInsulinInositol Polyphosphate 5-PhosphatasesNEURODEGENERATIONType 2 Diabetes Mellitusmedicine.diseasePhosphoric Monoester HydrolasesEndocrinologyDiabetes Mellitus Type 2chemistryImmunologySettore MED/26 - NeurologiaGeriatrics and Gerontologymedicine.symptomMetabolic syndromeSignal TransductionRejuvenation Research
researchProduct

Lipase elevation and type 1 diabetes mellitus related to immune checkpoint inhibitor therapy – A multicentre study of 90 patients from the German Der…

2021

Abstract Aim Immune checkpoint inhibition (ICI) triggers immune-related adverse events (irAEs). The relevance of lipase elevation remains unclear. Patients and methods Skin cancer patients with newly detected serum lipase elevation (at least twofold upper normal limit) or newly diagnosed type I diabetes mellitus upon ICI therapy were retrospectively collected at 14 German skin cancer centres. Results We identified 68 patients with lipase elevation occurring after a median time of 19 (range 1–181) weeks on ICI, 15 (22%) thereof had symptoms consistent with pancreatitis. Forty-seven patients (73%) had other irAE, mainly colitis. Discontinuation (n = 24, 35%) or interruption (n = 26, 38%) of I…

AdultBlood GlucoseMale0301 basic medicineCancer Researchmedicine.medical_specialtySkin NeoplasmsTime FactorsMedizinGastroenterologyThyroiditisYoung Adult03 medical and health sciences0302 clinical medicinePredictive Value of TestsGermanyInternal medicineDiabetes mellitusmedicineHumansLipaseAdverse effectImmune Checkpoint InhibitorsMelanomaAgedRetrospective StudiesAged 80 and overType 1 diabetesbiologybusiness.industryDiabetes; Diabetes mellitus; Immune checkpoint inhibitors; Immune-related adverse events; Ipilimumab; Lipase; Nivolumab; Pancreatitis; PD-1 inhibitor; Pembrolizumab; Adult; Aged; Aged 80 and over; Biomarkers; Blood Glucose; Diabetes Mellitus Type 1; Exocrine Pancreatic Insufficiency; Female; Germany; Humans; Immune Checkpoint Inhibitors; Lipase; Male; Melanoma; Middle Aged; Pancreatitis; Predictive Value of Tests; Retrospective Studies; Skin Neoplasms; Time Factors; Treatment Outcome; Up-Regulation; Young AdultLipaseMiddle Agedmedicine.diseaseUp-RegulationKetoacidosisDiabetes Mellitus Type 1Treatment Outcome030104 developmental biologyPancreatitisOncology030220 oncology & carcinogenesisbiology.proteinPancreatitisExocrine Pancreatic InsufficiencyFemaleSkin cancerbusinessBiomarkersEuropean Journal of Cancer
researchProduct

Glycemic variability in type 2 diabetes mellitus and acute coronary syndrome: liraglutide compared with insulin glargine: a pilot study

2020

Objective To explore the glucagon-like peptide-1 analogue liraglutide in the hospital setting in patients with type 2 diabetes mellitus (T2DM) and acute coronary syndrome and to evaluate the safety and efficacy and its impact on hospitalization and short-term glycemic variability (GV). Methods A 12-week, open-label, prospective, randomized pilot clinical study with parallel groups that compared liraglutide (group 1) with glargine (group 2) and its impact on glycemic control and GV. Results Thirteen patients were included. During hospitalization, mean glucose was 164.75 mg/dL (standard deviation [SD] 19.94) in group 1 and 166.69 mg/dL (38.22) in group 2. GV determined by CV and SD was 20.98 …

AdultBlood GlucoseMaleAcute coronary syndromemedicine.medical_specialtyProspective Clinical Research ReportMedicine (General)Hospital settingtype 2 diabetes mellitusGLP-1 receptor agonistInsulin Glargine030209 endocrinology & metabolismPilot Projects030204 cardiovascular system & hematologyHypoglycemiaBiochemistryacute coronary syndrome03 medical and health sciencesRandom Allocation0302 clinical medicineR5-920Internal medicineMedicineHumansHypoglycemic AgentsInsulinGlycemic variabilityGlucagon-like peptide 1 receptorGlycemicGlycated Hemoglobinliraglutidebusiness.industryInsulin glargineLiraglutideBiochemistry (medical)Type 2 Diabetes MellitusCell BiologyGeneral MedicineMiddle Agedmedicine.diseaseHypoglycemiaMetforminDiabetes Mellitus Type 2Glycemic IndexSpainFemalebusinessmedicine.drugJournal of International Medical Research
researchProduct

Correlation between different degree and duration of metabolic control and thyroid hormone levels in type 1 and type 2 diabetics.

1983

Thyroxine (T4), triiodothyronine (T3), reverse T3 (rT3) and HbA1c were assayed in 21 insulin-dependent (type 1) diabetics and in 45 non-insulin-dependent (type 2) diabetics with normal thyroid function and different levels of control, and were compared to values found in apparently healthy controls. rT3 and rT3/T3 ratio were significantly increased both in type 1 and type 2 diabetics. T3 and T4 were significantly lower in type 2 diabetics than in the controls. Significant positive correlations of HbA1c to rT3 (r = 0.63) and to rT3/T3 ratio (r = 0.53) were found in type 1, and in type 2 diabetics (HbA1c, rT3-r = 0.50), (HbA1c, rT3/T3-r = 0.37). There was no correlation between glycemia (BG),…

AdultBlood GlucoseMaleendocrine systemmedicine.medical_specialtyThyroid Hormonesendocrine system diseasesAdolescentTriiodothyronine ReverseEndocrinology Diabetes and MetabolismCorrelationEndocrinologyDiabetes mellitusInternal medicineInternal MedicinemedicineHumansAgedGlycated HemoglobinTriiodothyroninebusiness.industryThyroidType 2 Diabetes MellitusGeneral MedicineMiddle Agedmedicine.diseaseThyroxinemedicine.anatomical_structureEndocrinologyDiabetes Mellitus Type 1Diabetes Mellitus Type 2Thyroid hormonesMetabolic control analysisTriiodothyronineFemalebusinesshormones hormone substitutes and hormone antagonistsHormoneActa diabetologica latina
researchProduct